Investigational Device Exemption (IDE)
In the U.S. FDA framework, an Investigational Device Exemption is the regulatory mechanism that permits an unapproved device to be used in a clinical study to collect the safety and effectiveness data needed for later marketing. A novel implanted BCI is by default a significant-risk device, so before any human implantation the sponsor must obtain FDA approval of an IDE application together with approval by each site's ethics board. The application specifies the device, the investigational plan, manufacturing information, prior preclinical (bench and animal) testing, and a risk analysis.
An IDE is permission to study, not marketing approval: it comes with a limited number of investigators and participants, mandatory adverse-event reporting, and FDA authority to halt the study. The Early Feasibility Study (EFS) pathway is a specific form of IDE that lets a small first cohort proceed on limited preclinical data while the device design is still evolving, deliberately trading a smaller safety database for earlier human learning. Analogous mechanisms exist elsewhere, such as clinical-investigation authorization under the EU Medical Device Regulation.
A team seeking to implant a novel intracortical array in four people with paralysis files an Early Feasibility Study IDE. FDA review focuses on whether the preclinical animal data and manufacturing controls justify exposing a first human cohort, not on proving benefit; enrollment stays capped until interim safety data are reviewed.
An Early Feasibility Study IDE trades a smaller safety database for earlier human learning under a tight enrollment cap.
An IDE authorizes research use only; participants are not receiving an approved therapy and the device cannot be sold. Confusing an IDE study with approved treatment is a root of the therapeutic misconception.